A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.
- DOI
- 10.1093/annonc/mdw004
- Published
- 2016-01-22
- Container
- Ann Oncol
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/annonc/mdw004,
title = {A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.},
author = {Ciuleanu T and Bazin I and Lungulescu D and Miron L and Bondarenko I and Deptala A and Rodriguez-Torres M and Giantonio B and Fox NL and Wissel P and Egger J and Ding M and Kalyani RN and Humphreys R and Gribbin M and Sun W.},
year = {2016},
journal = {Ann Oncol},
doi = {10.1093/annonc/mdw004},
url = {https://doi.org/10.1093/annonc/mdw004}
}RIS
TY - JOUR TI - A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. AU - Ciuleanu T AU - Bazin I AU - Lungulescu D AU - Miron L AU - Bondarenko I AU - Deptala A AU - Rodriguez-Torres M AU - Giantonio B AU - Fox NL AU - Wissel P AU - Egger J AU - Ding M AU - Kalyani RN AU - Humphreys R AU - Gribbin M AU - Sun W. PY - 2016 JO - Ann Oncol DO - 10.1093/annonc/mdw004 UR - https://doi.org/10.1093/annonc/mdw004 ER -
APA
T, C., I, B., D, L., L, M., I, B., A, D., M, R., B, G., NL, F., P, W., J, E., M, D., RN, K., R, H., M, G., & W., S. (2016). A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.. Ann Oncol. https://doi.org/10.1093/annonc/mdw004
Source records
- europe-pmc · retrieved 2026-09-26T07:39:39.408Z